Company intelligence / Profile preview

Remergent

Freeport, New York, USA

Ownership: Private
Development stage: Other

Overview

Remergent was a biotechnology company primarily focused on the development and commercialization of DNA repair enzyme technologies for skin health and oncology. Founded by Dr. Daniel Yarosh, the company pioneered the use of liposome-encapsulated enzymes, such as T4 endonuclease V and OGG1, to repair DNA damage caused by UV radiation. Its product line included specialized skincare treatments designed to prevent skin cancer and reverse the signs of photoaging. The company's underlying technology and brand were eventually integrated into larger dermatological and cosmetic portfolios following its acquisition.

Therapeutic areas: Dermatology
Modalities: ProteinEnzymeSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Remergent.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Remergent.

Explore the full profile